Can Kadcyla give Roche a softer landing when Herceptin biosims hit? New data could help
admin 15th October 2018 Uncategorised 0Roche’s Kadcyla needs some oomph, and the Swiss drugmaker’s new data might just do the trick. The company is teeing up a new filing for its next-generation breast cancer drug, hoping to gin up more sales as its ancestor, Herceptin, moves ever closer to biosimilar competition in the U.S.
More: Can Kadcyla give Roche a softer landing when Herceptin biosims hit? New data could help
Source: fierce